



Attorney Docket No.: 10082.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Kjærulff et al.

Confirmation No: 5518

Serial No.: 09/981,009

Group Art Unit: 1645 *38*

Filed: October 16, 2001

Examiner: ~~To be assigned~~

For: Transgenic Plants

Bui

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Box DD
Commissioner for Patents
Washington, DC 20231

RECEIVED
APR 08 2002
TECH CENTER 1600/2900

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Box DD
Commissioner for Patents
Washington, DC 20231

on April 1, 2002.

Julie Tabarovsky
(name of person mailing paper)

J. Tabarovsky
(signature of person mailing paper)



Attorney Docket No.: 10082.200-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Kjærulff et al.

Confirmation No: 5518

Serial No.: 09/981,009

Group Art Unit: 1645

Filed: October 16, 2001

Examiner: To be assigned

For: Transgenic Plants

PATENT
RECEIVED
APR 08 2002
TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(c)

Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:


1. Collins et al., Clinical and Experimental Allergy, Vol. 26, pp. 36-42, (1996)
2. Schoofs et al., The Journal of Immunology, Vol. 140, No.2, pp. 611-616, (1988)
3. Walsh et al., Journal of Immunological Methods, Vol. 121, pp.275-280, (1989)
4. Sakakibara et al., J. Vet. Med. Sci., Vol. 60, No. 5, pp.599-605, (1998)
5. Kammerer et al., clinical and Experimental Allergy, Vol. 27, pp. 1016-1026, (1997)
6. WO 00/26230
7. WO 01/49830
8. WO 99/53038
9. WO 00/47610
10. WO 00/52154
11. WO 92/10755
12. WO 99/47680
13. WO 99/38978

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application, or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due.

Respectfully submitted,

Date: April 1, 2002

A handwritten signature in black ink, appearing to read "Elias J. Lambiris", is written over a horizontal line.

Elias J. Lambiris, Reg. No. 33,728
Novozymes North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

(Use several sheets if necessary)

Applicant

Kjærulff et al.

Filing Date

October 16, 2001

Group	Mean	SD	95% CI
Control	1.0	0.0	1.0
Low	1.0	0.0	1.0
High	1.0	0.0	1.0

1645

U. S. PATENT DOCUMENTS

RECEIVED

APR 08 2002

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

TRANSLATION

YES

NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Collins et al., *Clinical and Experimental Allergy*, Vol. 26, pp. 36-42, (1996)

Schoofs et al., The Journal of Immunology, Vol. 140, No.2, pp. 611-616, (1988)

Walsh et al., Journal of Immunological Methods, Vol. 121, pp.275-280, (1989)

Sakakibara et al., J. Vet. Med. Sci., Vol. 60, No. 5, pp.599-605, (1998)

Kammerer et al., clinical and Experimental Allergy, Vol. 27, pp. 1016-1026, (1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U. S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Atty. Docket No.
10082.200-US

Serial No.
09/981,009

APR 04 2007
ST

187 INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several ³ sheets if necessary)

Applicant
Kjærulff et al.

Filing Date
October 16, 2001

Group
1645

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
						TECH CENTER 1600/29
						APR 8 2002

FOREIGN PATENT DOCUMENTS

[illegible][illegible][illegible]

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.